TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04580810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT4CBT in the Black Church
Description: Use of Computer Based Treatment for Cognitive Behavioral Therapy for alcohol use disorder offered in a Black church setting
Study: NCT05146141

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Bent-arm throw exercises
Description: The participants will have to perform bent-arm throw exercises 5 minutes before each training session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bent-arm throw exercises
Description: The participants will have to perform bent-arm throw exercises 5 minutes before each training session
Study: NCT05664620

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Risk Stratification Tool
Description: Patients will be allocated to three groups (Low,medium and high risk) by using the Risk Stratification Tool, and High risk patients will receive multidisciplinary treatment assigned to them by a physician
Study: NCT04900402

Intervention type: OTHER
Intervention: Survey
Description: International Physical Activity Questionnaire Short Form (IPAQ) and Quality of Life Scale for Children (PedsQL)

Intervention type: OTHER
Intervention: Survey
Description: International Physical Activity Questionnaire Short Form (IPAQ) and Quality of Life Scale for Children (PedsQL)
Study: NCT06126640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: Lyophilized powder injection, 100mg / bottle, intravenous drip

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab Emtansine
Description: Lyophilized powder injection, 160mg / bottle, 100mg / bottle, intravenous drip
Study: NCT05850078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FB101
Description: Intervention will test effects on changes to the vaginal microbiome of FB101 versus diluted FB101 versus placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FB101
Description: Intervention will test effects on changes to the vaginal microbiome of FB101 versus diluted FB101 versus placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: FB101
Description: Intervention will test effects on changes to the vaginal microbiome of FB101 versus diluted FB101 versus placebo
Study: NCT05239845

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic
Description: The bioactive ingredients used in this study include bovine milk fat globule membrane (MFGM), bovine lactoferrin and a prebiotic blend of polydextrose and galactooligosaccharides (PDX/GOS).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic
Description: The bioactive ingredients used in this study include bovine milk fat globule membrane (MFGM), bovine lactoferrin and a prebiotic blend of polydextrose and galactooligosaccharides (PDX/GOS).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic
Description: The bioactive ingredients used in this study include bovine milk fat globule membrane (MFGM), bovine lactoferrin and a prebiotic blend of polydextrose and galactooligosaccharides (PDX/GOS).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Maltodextrin
Study: NCT06020924

Intervention type: OTHER
Intervention: No intervention
Description: This study is a retrospective observational study without intervention.

Intervention type: OTHER
Intervention: No intervention
Description: This study is a retrospective observational study without intervention.
Study: NCT05936762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neoial HC
Description: Patients with severe knee osteoarthritis were enrolled in the clinical study and treated with 3 injections of 40 mg NEOIAL HC (HA sodium salt at 2% with two molecular weights 20% with pm at 400 kD and 80% between 1200 and 1500 kD t + collagen) at a distance of 1 week from each other, followed by a fourth infiltration of the same product at a distance of 1 month from the third.Patients were followed up with baseline clinical evaluation, reporting of adverse events after each single infiltration and subsequently at the end of treatment, 3, 6 months follow-up.
Study: NCT05588427

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: A total of 240g ketone ester supplementation will be provided in one of the 28h experimental sessions in order to establish intermittent exogenous ketosis. Sucralose (5% w/w) is added to the ketone ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water, 5% sucralose (w/w), octaacetate (1 mM)
Study: NCT06129890

Intervention type: DEVICE
Group type: OTHER
Intervention: Repetitive transcranial magnetic stimulation (rTMS) - M1/DLPFC
Description: Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of M1 then rTMS of DLPFC.

Intervention type: DEVICE
Group type: OTHER
Intervention: Repetitive transcranial magnetic stimulation (rTMS) - DLPFC/M1
Description: Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of DLPFC then rTMS of M1.
Study: NCT04550182

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positioning schedule
Description: The Braden scale will be collected every morning. Patients' care will be friction and repositioning applied at a frequency defined by the Braden scale:~6 ≥ Braden ≤ 8: alternate positioning every 2 hours 9 ≥Braden ≤ 13: alternate positioning every 4 hours 14 ≥ Braden ≤ 17: No alternative of the positioning required, but a friction and an evaluation of the cutaneous state every 6 hours.~18 ≥Braden ≤ 23: No alternative of the positioning required, but a friction and an evaluation of the cutaneous state every 12 hours.~Positioning will alternate semi-lateral decubitus at 30, semi-Fowler 30° -30°, half-sitting position 45° with elevation of the lower limbs.~A medical prescription as part of the daily reassessed care will ensure the absence of absolute contraindication to the mobilization or contraindication to certain positions.Friction will be performed during repositioning.
Study: NCT06438328

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Left/ Right affected arm
Description: Therapeutic exercises: eccentric and concentric exercises and wrist isometrics 10 repetitions of 3 sets with 10 seconds interval

Intervention type: OTHER
Group type: OTHER
Intervention: Grip strength
Description: assessed by using modified sphygmomanometer in which it first inflated to 100 mmHg with closed valve. The pressure was reduced to 20mmHg and the resisted wrist extension performed at baseline and at the 4th week.
Study: NCT04531267

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Individualized dosage of calcium and magnesium
Description: Participants' diet will be assessed by food frequency questionnaire to obtain calcium and magnesium intake. Individualized dosage of dietary supplements will be provided to maintain a calcium/magnesium ratio as 2.3. Participants will stay with the original medication plan.
Study: NCT06351033

Intervention type: DIETARY_SUPPLEMENT
Intervention: High ozonide (HOO) ozonated oil
Description: ozonated oil with high ozonides (HOO) administered orally (os) in gastro-resistant capsules
Study: NCT04987619

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Subjects will drink juice 120 minutes before each visit

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Capri-Sun
Description: 70 mL of blackcurrant beverage, which is depleted of NO3- will be taken 120 min before each visit.
Study: NCT01268709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxepin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nortriptyline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05241808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girls Can...Move!
Description: Girls Can...Move! is an 8-week intervention designed to increase physical literacy and physical activity among middle school aged girls. One-hour, in-person sessions will be held twice per week for a total of 16 sessions. Each session involves: a brief educational lesson related to physical activity participation, a 30-minute group physical activity session, and a take-home challenge. The physical activities will prioritize enjoyment of physical activity and promote the development of movement competence. These activities may include: yoga; Zumba; Pilates; strength training; kick boxing; circuit training; etc.
Study: NCT05608447

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FMT capsules
Description: FMT capsules containing extensively screened donor stool.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules that do not contain donor stool or any active drug.
Study: NCT05805514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal source of food and psychosocial stimulation
Description: 209 mother-child pair will receive the animal source of food and psychosocial stimulation for 12 months. Child will be recruited within 6-12 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal source of food
Description: 209 mother-child pair will receive the animal source of food for 12 months. Child will be recruited within 6-12 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 209 mother-child pair will receive the control package for 12 months. Child will be recruited within 6-12 months.
Study: NCT04934826

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed Proteins
Description: Patients in experimental arm will receive a test meal based on marked hydrolyzed proteins

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intact proteins
Description: Patients in active comparator arm will receive a meal based on intact marked proteins.
Study: NCT04568837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 20 Mg
Description: 20 mg of Prednisone or 1 mL of 4 mg/mL Dexamethasone Sodium Phosphate will be administered each day for participants in the intervention group
Study: NCT06355882

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anesthetic infiltration
Description: Application of local dental anesthesia with two cartridges (3,6 mL) for dental procedures (tooth extraction or periodontal treatment) in patients with low cardiac output syndrome.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anesthetic infiltration
Description: Application of local dental anesthesia with two cartridges (3,6 mL) for dental procedures (tooth extraction or periodontal treatment) in patients with low cardiac output syndrome.
Study: NCT06546865

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22F Sheath Size
Description: Participants in this group will have the 22F sheath size used in their procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 26F Sheath Size
Description: Participants in this group will have the 26F sheath size used in their procedure.
Study: NCT05116657

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal Lavage and Oral Wash
Description: * Nasal Lavage: The nasal lavage will be performed using a spray technique. Using a disposable metered-dose inhaler (100 µl per spray), room temperature saline will be sprayed in one nostril while the other nostril is closed. After 5 sprays, the subject will gently exhale through the lavaged nostril and the fluid will be collected in a specimen cup. The procedure will be repeated a minimum of 8 times and a maximum of 15 times in each nostril. After collection, the sample will be placed on ice and processed within 2 hours.~* Oral Rinse: Oral samples will be collected using a standardized procedure in accordance with the Manual of Procedures for Human Microbiome Project.Study participants will rinse their mouth (swish/gargle) with 15 mL sterile normal saline for 1 min, and will expectorate the contents of the mouth into a 50 mL centrifuge tube. Sample should be kept cold on ice until processing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal Lavage and Oral Wash
Description: * Nasal Lavage: The nasal lavage will be performed using a spray technique. Using a disposable metered-dose inhaler (100 µl per spray), room temperature saline will be sprayed in one nostril while the other nostril is closed. After 5 sprays, the subject will gently exhale through the lavaged nostril and the fluid will be collected in a specimen cup. The procedure will be repeated a minimum of 8 times and a maximum of 15 times in each nostril. After collection, the sample will be placed on ice and processed within 2 hours.~* Oral Rinse: Oral samples will be collected using a standardized procedure in accordance with the Manual of Procedures for Human Microbiome Project.Study participants will rinse their mouth (swish/gargle) with 15 mL sterile normal saline for 1 min, and will expectorate the contents of the mouth into a 50 mL centrifuge tube. Sample should be kept cold on ice until processing.
Study: NCT05249049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-OPRA Implant System for Transtibial Amputees
Description: The e-OPRA System for transtibial use consists of an anchorage element (Fixture), which is surgically inserted in the medullary canal of the amputated skeleton of the lower limb. The skin penetrating e-Abutment is then inserted and secured with the e-Abutment screw. To allow the system to be used with an external neuro-mechanical prosthesis, soft tissues from the distal limb are preserved incorporated into the residual limb. Muscle electrodes are then placed in the neuro-muscular constructs. After a rehabilitation program, in everyday use, the implanted e-OPRA device will be used by the patient with the Axor TC and their commercially available prosthesis. However, the modified version of the implant will allow the patient to use a powered neuro-mechanical prosthesis during specified testing scenarios.
Study: NCT05787847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for Abstinence
Description: Participants in the incentives for abstinence condition will have the opportunity to earn financial incentives for abstaining from stimulant use.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Education
Description: The Health Education condition is based on a previous intervention used as a control in a number of other studies. Sessions consist of an educational program addressing a variety of health, wellness, and lifestyle topics adapted from a previously implemented wellness manual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: The Health Education condition is based on a previous intervention used as a control in a number of other studies. Sessions consist of an educational program addressing a variety of health, wellness, and lifestyle topics adapted from a previously implemented wellness manual.
Study: NCT05106530

Intervention type: DIAGNOSTIC_TEST
Intervention: Holter, ECG
Description: Incidence of arrhythmias in Holter monitoring among coronary artery ectasia patients as compared to normal coronary artery patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Holter, ECG
Description: Incidence of arrhythmias in Holter monitoring among coronary artery ectasia patients as compared to normal coronary artery patients.
Study: NCT05525663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation Intervention
Description: progressive, multi-domain rehabilitation and exercise training intervention
Study: NCT06075823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEER
Description: transcatheter edge-to-edge mitral valve repair for significant mitral regurgitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy
Description: optimal heart failure management of ATTR-CM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy
Description: optimal heart failure management of ATTR-CM
Study: NCT05926921

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: music
Description: Brahms' Lullaby will be played from a speaker at 50 decibels
Study: NCT05319860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV)
Description: Standard of care for CINV includes anti-nausea medication as needed after chemotherapy regimen given for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV)
Description: Standard of care for CINV includes anti-nausea medication as needed after chemotherapy regimen given for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatherapy Care
Description: An aromatherapy inhaler provided for use as needed after chemotherapy regimen given for up to 12 weeks. One normal inhale is equal to one dose of aromatherapy. Participants can use the aromatherapy as often as needed.
Study: NCT05747989

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: two-component skin adhesive, Glubran Tiss 2
Description: After subcutaneous stitches a two-component skin adhesive, Glubran Tiss 2®, will be applied. G Each subject will receive 0.35 mL of Glubran Tiss® in the open wound, and before bandaging, subjects rested for 20 minutes for a polymerization process.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: skin is stitched with transcutaneous nylon sutures
Description: The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0
Study: NCT06488677

Intervention type: BEHAVIORAL
Intervention: Lifestyle changes (diet and physical activity)
Description: Nurse-led telephone personalized dietary and PA advice

Intervention type: BEHAVIORAL
Intervention: Lifestyle changes (diet and physical activity)
Description: Nurse-led telephone personalized dietary and PA advice
Study: NCT04737044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study 1: MRBS
Description: MRBS as added sugar based on their habitual diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study 2: White sugar & education module
Description: White sugar for daily usage (\<10% daily energy intake)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study 2: MRBS & education module
Description: MRBS for daily usage (\<10% daily energy intake)
Study: NCT05934214

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Reports associated with an an Immune checkpoint inhibitor with a status of Suspect or Interacting~ICI will include the following list of FDA-apporved ICIs:~nivolumab, pembrolizumab, cemiplimab, dostarlimab, durvalumab, atezolizumab, avelumab, ipilimumab, tremelimumab, relatlimab
Study: NCT05394493

Intervention type: DRUG
Intervention: avelumab
Description: as provided in real world setting

Intervention type: DRUG
Intervention: axitinib
Description: as provided in real world settings
Study: NCT05371873

Intervention type: PROCEDURE
Intervention: Liver resection method
Description: undergo anatomical or non-anatomical resection of liver cancer

Intervention type: PROCEDURE
Intervention: Liver resection method
Description: undergo anatomical or non-anatomical resection of liver cancer
Study: NCT05971849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kisspeptin 112-121
Description: IV infusion of kisspeptin 112-121 x 24 hours; up to two IV boluses of kisspeptin
Study: NCT05622162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiopharmaceutical 18F-JK-PSMA-7
Description: The Investigational product 18F-JK-PSMA-7 is a diagnostic radiopharmaceutical for use with positron emission tomography.~18F-JK-PSMA-7 is administered as direct intravenous injection. One single administration of 2-4 MBq/kg of 18F-JK-PSMA-7 is scheduled in each patient included in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiopharmaceutical 18F-Fluorocholine
Description: The active substance of Comparator is 18F-Fluorocholine. The Comparator will be a 18F-Fluorocholine with a Marketing Authorisation in Italy that will be used in compliance with its Summary of Product Characteristics (SmPC).~18F-Fluorocholine is administrated as direct intravenous injection. One single administration of 18F-Fluorocholine is scheduled in each patient included in this study.
Study: NCT05208918

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural steroid
Description: Injection of Depo-Medrol of affected dermatomes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRF plus steroids injection
Description: Pulsed radiofrequency with temperature 42 degrees for 6 minutes to be applied to the dorsal root ganglion plus injection of Depo-Medrol of affected dermatomes
Study: NCT05873660

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study: NCT05003271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program (virtual/remote)
Description: Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program (virtual/remote)
Description: Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions.
Study: NCT06103331

Intervention type: OTHER
Intervention: Invasive Fungal disease surveillance
Description: Management of invasive fungal infection according to pathogen identification and susceptibility report.

Intervention type: OTHER
Intervention: Invasive Fungal disease surveillance
Description: Management of invasive fungal infection according to pathogen identification and susceptibility report.
Study: NCT05596097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib, 180mg, bid, p.o., d1-28; Treatment cycles every 28 days